This article is more than 5 years old. Information may no longer be current.

Endocrine Society praises Novo Nordisk’s commitment to affordable insulin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In a recent statement, the Endocrine Society applauded Novo Nordisk’s partnership with CVS Caremark to create a prescription saving program that offers discounts on certain medications, including insulin.

The program, Reduced Rx, went into effect on May 10 and allows people with diabetes to purchase human insulin (Novolin, Novo Nordisk) for $25 per 10 mL vial, which is a potential $100 savings, according to the statement.

The Endocrine Society is “encouraged” by Novo Nordisk’s efforts and continues to believe that transparency across the insulin supply chain and advocacy can result in making this life-saving medication affordable for those who need it, according to the statement.